X0609 4 2026-09-03 0001228627 Opus Genetics, Inc. IRD 0001504983 Gagnon Robert E. false C/O OPUS GENETICS, INC. 8 DAVIS DRIVE, SUITE 220 DURHAM NC 27713 true Chief Financial Officer false Common Stock 2026-09-03 4 S 0 28000 4.5433 D 556375 D A portion of the shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Issuer, to satisfy tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units, and the remainder of the shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 30, 2026. The Rule 10b5-1 trading plan is a pre-arranged written trading plan pursuant to which shares of the Issuer's common stock are sold automatically based on a predetermined formula that was established by the Reporting Person at a time when the Reporting Person was not aware of any material nonpublic information about the Issuer. The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $4.29 to $4.79, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Amy Rabourn, by Power of Attorney 2026-09-08